IMMP Immutep LTD ADR
8,915
$3.00
$0.18
(6.38%)
| Watchers | 8,915 |
| 52-Wk Low | $1.50 |
| 52-Wk High | $3.90 |
| Market Cap | $356.65M |
| Volume | 2,161.00 |
| 52-Wk High | $3.90 |
| 52-Wk Low | $1.50 |
Immutep Limited (NASDAQ:IMMP) Short Interest Up 5.6% in MarchZolmax • about 1 month ago
Immutep Limited (NASDAQ:IMMP - Get Free Report) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 1,140,000 shares, an increase...
Share to Feed
Immutep Limited (NASDAQ:IMMP - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $2.35 and traded as high as $2.47. Immutep...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who...
Immutep Limited (NASDAQ:IMMP Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling...
Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Media Release SYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep or the Company ), a clinical-stage biotechnology company developing novel...